Dermira, Inc.
275 Middlefield Road
Suite 150
Menlo Park
California
94025
United States
Tel: (650) 421-7200
Fax: 650-365-3410
Website: http://www.dermira.com/
Email: info@dermira.com
112 articles about Dermira, Inc.
-
Dermira Highlights New Long-Term Safety Data For Glycopyrronium Tosylate In Primary Axillary Hyperhidrosis At Fall Clinical Dermatology Conference
10/13/2017
-
Dermira Completes Patient Enrollment In Two Phase III Pivotal Trials Of Olumacostat Glasaretil For The Treatment Of Acne Vulgaris
10/5/2017
-
Dermira Announces Early Termination Of The Hart-Scott-Rodino Waiting Period For License To Lebrikizumab
9/15/2017
-
Dermira, UCB Group Release: New CIMZIA (Certolizumab Pegol) Findings Presented At European Academy Of Dermatology And Venereology (EADV) Congress
9/14/2017
-
Dermira Presents New Data Showing Impact Of Primary Axillary Hyperhidrosis On Patients
9/13/2017
-
Dermira Presents New Data On Late-Stage Programs At Leading European Dermatology Congress
9/7/2017
-
Dermira Reports Second Quarter 2017 Financial Results And Provides Corporate Update
8/8/2017
-
Bay Area Dermira to License Exclusive, Worldwide Rights to Roche's Lebrikizumab
8/8/2017
-
UCB SA And Dermira Announce U.S. And EU Regulatory Submissions For CIMZIA (Certolizumab Pegol) For The Treatment Of Moderate-To-Severe Chronic Plaque Psoriasis
7/25/2017
-
Dermira Release: Newly Published Nonclinical Data Highlight The Role Of Olumacostat Glasaretil In Sebum Inhibition
6/26/2017
-
Dermira Announces Appointment Of Ian Clements As Vice President, Investor Relations
6/6/2017
-
Dermira Announces Closing of 3.00% Convertible Senior Notes Offering
5/17/2017
-
Dermira Prices Offering Of $250 Million Of 3.00% Convertible Senior Notes
5/11/2017
-
Dermira Announces Proposed Offering Of $250 Million Of Convertible Senior Notes
5/10/2017
-
Dermira Reports First Quarter 2017 Financial Results And Provides Corporate Update
5/9/2017
-
Dermira Presents New Data Highlighting Patient Outcomes In Axillary Hyperhidrosis At Maui Derm Meeting
3/21/2017
-
Dermira Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters’ Option To Purchase Additional Shares
3/8/2017
-
Dermira And UCB Group Release: New CIMZIA (Certolizumab Pegol) Data In Moderate-To-Severe Plaque Psoriasis And Psoriatic Arthritis Presented At American Academy of Dermatology 2017 Annual Meeting
3/6/2017
-
Dermira Presents New Data In Primary Axillary Hyperhidrosis And Acne At American Academy of Dermatology 2017 Annual Meeting
3/3/2017
-
Dermira Prices $168.5 Million Public Offering Of Common Stock
3/2/2017